Plan B Litigation Puts Teva At Odds With Advocacy Group
This article was originally published in The Tan Sheet
Executive Summary
Teva Pharmaceutical Industries and the Center for Reproductive Rights are butting heads over the company’s right to OTC market exclusivity for Plan B One-Step. CRR says the firm cannot assert a right to exclusivity that was never granted.
You may also be interested in...
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
NaZura’s Lovidia Weight-Loss Supplement Strategy Focused On Brand Building
NaZura BioHealth, spun out from Elcelyx Therapeutics, will market its Lovidia weight-loss product in 2014 when it launches into the direct-response channel, before potential suitors get serious about acquiring the brand.
Certain Dri Antiperspirant Sweats It Out Against Big Players
With a thicker, “drip-free” reformulation of Certain Dri launching in January 2014, DSE Healthcare Solutions hopes its clinical-strength roll-on antiperspirant will appeal to more consumers with hyperhidrosis as well as those concerned about but not diagnosed with excessive perspiration.